We developed a rapid, simple and sensitive LC/MS/MS method for the simultaneous quantitation of tegafur (FT) and gimeracil (CDHP) in human plasma with a concentration range of 20 -5000 and 2 -500 ng/mL, respectively. Methanol was chosen as a precipitation agent for sample preparation. Chromatographic separation was performed on an inertsil ODS-3 C18 column using 1.0% formic acid in water and methanol (80/20, v/v) at a flow rate of 0.3 mL/min. The MS detection was operated with selected reaction monitoring (SRM) in the positive-ion mode. The matrix effect ranged from -8.9 to 7.8% for all analytes. The intra-and inter-day precisions were less than 8.6 and 9.5%, and the accuracy was within ±7.5% for all analytes, respectively. The mean recoveries were 76.5 ± 5.2 and 78.3 ± 5.9% for FT and CDHP, respectively. The analytes were stable under all possible conditions of storing and handling for each compound.
Tegafur (FT), a 2-tetrahydrofuranyl derivative of 5-fluorouracil (5-FU), acts as a prodrug of 5-FU, which could increase the oral bioavailability and produce comparatively little myelosuppression. 1 FT is also an ingredient of S-1, which is a novel oral agent consisting of three pharmacological agents: FT, gimeracil (CDHP) and potassium oxonate (Oxo). FT is metabolically activated to 5-FU predominantly by cytochrome P450 2A6 in the liver. 2 Then, 5-FU is metabolized to 5-fluoro-5,6-dihydrouracil (FUH2) by dihydropyrimidine dehydrogenase (DPD). 3, 4 Approximately 90% of the administered dose of 5-FU is metabolized by DPD before exerting antitumor activity. 5 The inhibition of DPD activity is therefore likely to potentiate the antitumor activity of 5-FU in vivo. CDHP (5-chloro-2,4-dihydroxypyridine) is a very potent reversible competitive inhibitor of DPD, 180-fold more potent than DPD-inhibitory activity of uracil, which is confirmed to be an effective DPD inhibitor. 6 When FT is combined with CDHP, CDHP as modulator could prevent the degradation of 5-FU, but has no direct effect on 5-FU anabolism. [6] [7] [8] Thus, the combination of CDHP and FT is successful to obtain an effect similar to that of long-term continuous intravenous injection of 5-FU, and increases the 5-FU concentrations in the tumor by five to ten times compared to FT alone, or 5-FU itself. 9 Several methods for the quantitation of FT and CDHP in human plasma have been reported. High-performance liquid chromatography (HPLC) for FT and gas chromatography/mass spectrometry (GC/MS) for CDHP are the most widely used instrumental techniques in the analysis of plasma samples simultaneously consisting of FT and CDHP. [9] [10] [11] [12] [13] [14] [15] [16] These methods are complicated, using two different analytical systems and a complex apparatus, involving a derivatization step before analysis, and requiring a long runtime. On the other hand, HPLC or LC/MS/MS methods for the quantification of FT alone in plasma samples have also been reported. [17] [18] [19] [20] These methods require a time-consuming extraction procedure, and a 20 -30 min runtime. There was a paper about the HPLC method for the determination of CDHP alone for an in vitro sample, 6 but this method is not suitable for detailed pharmacokinetic studies in humans, because of poor specificity or inadequate sensitivity.
To our knowledge, to date, no LC/MS/MS method for the simultaneous determination of FT and CDHP in human plasma has been reported. Therefore, we developed and validated a rapid, simple and sensitive LC/MS/MS method for the simultaneous quantitation of FT and CDHP in human plasma to compensate for any disadvantage of the previous methods. The method can be applied to pharmacokinetic studies of these drugs and to the optimization of an individual dose.
Experimental

Chemicals and reagents
FT and CDHP were supplied by Shenzhen Neptunus Pharmaceutical Co., Ltd. (Shenzhen, China). Strychnine (IS) was purchased from National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). HPLC-grades of methanol and formic acid were from Tianjin Concord Tech Reagent Co., Ltd. (Tianjin, China). All other reagents were of analytical grade. Distilled water, prepared from demineralized water using an SYZ550 quartz pure water distiller (Tianjin Xinzhou Tech Co. Ltd., Tianjin, China), was used throughout the experiment.
Instrumentation and chromatographic/mass spectrometric conditions
The LC/MS/MS system consists of a Surveyor auto-sampler, a Surveyor LC pump, a TSQ Quantum Discovery Max TM triple-quadrupole mass spectrometer and Xcalibur 1.4 software (Thermo Finigan, USA). The LC column was an inertsil ODS-3 C18 column (50 mm × 2.1 mm, 5 μm, GL Science Inc., Tokyo, Japan) maintained at 25 C. The mobile phase consisted of 1.0% formic acid in water and methanol (80/20, v/v) for 3.5 min with a flow rate of 0.3 mL/min. The injection volume was 10 μL.
The mass spectrometer was equipped with an electrospray ionization (ESI) source. The ESI source was operated in a positive-ion mode with a spray voltage of 4500 V. The sheath gas and auxiliary gas were nitrogen delivered at 50 psi and at 2 L/min, respectively. The capillary temperature was 280 C. The collision gas was argon and the collision gas pressure was 0.7 mTorr. The selected reaction monitoring (SRM) mode was used to detect a specific transition of the precursor ion to product ion for FT ( 
Preparation of standards
The stock standard solutions of FT, CDHP, and IS were dissolved in methanol at 1.0 mg/mL, respectively. A series of standard working solutions containing binary mixtures of FT and CDHP were prepared by mixing and further serially diluting the stock standard solutions with methanol to obtain the following concentrations: 20, 50, 200, 500, 2000 and 5000 ng/mL for FT and 2, 5, 20, 50, 200 and 500 ng/mL for CDHP, respectively. An IS working solution (100 ng/mL) was also prepared by diluting the 1 mg/mL IS stock solution with methanol. All of the solutions were kept in brown volumetric flasks at 4 C.
Aliquot (100 μL) working standard solutions were spiked in 100 μL blank human plasma to obtain calibration standard samples that contained FT and CDHP concentrations in plasma ranging from 20 to 5000 ng/mL and from 2 to 500 ng/mL. Quality control (QC) samples were prepared in a similar manner at three low, medium and high levels (50, 500, 2000 ng/mL for FT and 5, 50, 200 ng/mL for CDHP). All of the spiked plasma samples were then treated according to sample-preparation procedure.
Sample preparation
Sample preparation was performed using a protein precipitate. An aliquot (100 μL) plasma sample and 100 μL methanol or 100 μL working standard solutions were added to a 200-μL IS working solution in polypropylene tubes. Subsequently, the tubes were vigorously vortex-mixed for 30 s to precipitate plasma proteins, and centrifuged for 5 min at 6000g. Upper organic layers of a 300-μL aliquot were transferred to glass tubes and evaporated to dryness at 40 C under a stream of nitrogen. The residues were reconstituted in a 100-μL mobile phase, vortex-mixed and centrifuged again for 5 min at 6000g before the supernatant was injected into the LC/MS/MS system for analysis.
Method validation
Selectivity. To investigate the selectivity of the method, blank human plasma samples from six different healthy volunteers were pretreated and analyzed to test the potential interferences of endogenous compounds co-eluting with analytes and IS. Chromatographic peaks of analytes and IS were identified on the basis of their retention times and SRM responses. Matrix effect. The matrix effect due to the plasma matrix was used to evaluate the ion suppression/enhancement in a signal when comparing the absolute response of QC samples after the pretreatment mentioned above with the absolute response of reconstitution samples extracted blank plasma sample spiking with analytes. Experiments were performed at the three QC levels, in triplicate. Linearity. Calibration curves over a linear range from 20 (2) to 5000 (500) ng/mL for FT (CDHP) in human plasma were assayed in triplicate on three consecutive days. Calibration curves for FT and CDHP were generated by plotting the peak-area ratio (analytes/IS) versus the spiked concentrations of each compound. Calibration graphs were obtained using the least-squares method. A linear-regression analysis was assessed with a weighting factor of 1/x 2 , and deviations of these back-calculated concentrations from the spiked concentrations were set to within ±15% (±20% for the lower limits of quantitation). The correlation coefficient and the deviation reflected the assay performance over the concentration range. Precision and accuracy. The intra-and inter-day precisions were assessed from the results of six replicates of the low, medium and high QC samples (50, 500, 2000 ng/mL for FT, and 5, 50, 200 ng/mL for CDHP) on three consecutive days. The assay precision was calculated by using a one-way analysis of variance, and expressed as the relative standard deviation (RSD). The assay accuracy was determined by calculating the percentage deviation (the ratio of the difference between the measured concentration and the spiked concentration to the spiked concentration) and expressed as the relative error (RE). The acceptable intra-and inter-day precision and accuracy were required to be within ±15%. Lower limits of quantitation. The lower limits of quantitation (LLOQ) of FT and CDHP were assessed to be the lowest concentrations on the calibration curve that could be quantitatively determined with a suitable precision of less than 20%, and an accuracy within ±20%. The LLOQ was established based on six replicates, independent of the calibration standards. Recovery. The recoveries of FT and CDHP were determined by comparing the peak areas obtained from these prepared plasma samples described above to those obtained from the direct injection of standard solutions without preparation at the same concentrations. Experiments were performed at the three QC concentration levels, in triplicate. Stability. The sample stability experiments were aimed at studying all of the possible conditions that the samples might be exposed to during storing and handling. The stability of analytes in human plasma was investigated by comparing the measured concentrations of triplicate low, medium and high QC samples with the spiked concentrations under the following four storage conditions: A) The short-term storage stability was assessed by detecting samples after storage for 4 h at room temperature. B) For freeze-thaw stability, the plasma samples were determined through three freeze (-20 C)-thaw (room temperature) cycles. C) For the stability of the processed plasma samples in an auto-sampler, QC samples were extracted and placed in an auto-sampler at 4 C for a period of 12 h, and then injected for analysis. D) The long-term stability was studied by assaying the plasma samples after 30 days of storage at -20 C. All samples were analyzed together with calibration curves that were freshly prepared. The analytes were considered to be stable when the percentage deviation was within ±15%.
Results and Discussion
Chromatographic conditions
We investigated multiple chromatographic conditions. An inertsil ODS-3 C18 column (50 mm × 2.1 mm i.d., 5 μm, GL Science Inc., Tokyo, Japan) was finally used for chromatographic separation. A mobile phase consisting of methanol and 1% formic acid (20:80, v/v) was found to be optimal for this study. The addition of 1% formic acid was made to obtain a better peak shape, and to increase the protonated efficiency and sensitivity.
The chromatographic conditions provided a symmetric peak shape, good sensitivity and a short runtime (3.5 min) for FT, CDHP and IS. Under the optimized conditions, no significant endogenous interference was found.
Mass spectrometric conditions
By comparing the full-scan mass spectra of FT and CDHP in the positive-ion mode with that in the negative-ion mode, we found that the signal intensity obtained in the positive-ion mode was much higher than that in the negative-ion mode. Thus, all detection was carried out using the predominantly positive-ion mode. The full-scan positive-ion mass spectrum showed that the precursor ions of FT, CDHP and IS were the protonated molecules 
Internal standard
For selecting the ideal internal standard, a similar processing method and a suitable retention time are of significant importance. Several compounds were tried, and strychnine was finally adopted as an internal standard, because of a similarity to the analytes in chromatographic behavior, mass spectrometric conditions (ionization) and recovery.
Sample preparation
Since a great number of samples need to be analyzed in a pharmacokinetic study, a simple, rapid and economic sample preparation is both necessary and critical. Plasma samples consisting of FT and CDHP, which have different chemical and physical properties, were all to be pretreated by liquid-liquid extraction using dichloromethane, isopropanol:ethyl acetate (15:85, v/v) and n-propanol:ether (16:84, v/v) as an extraction agent. [9] [10] [11] [12] [13] [14] 16, 18, 20 However, protein precipitation was used for sample preparation after comparing the liquid-liquid extraction, and methanol was chosen as a precipitation agent in this study. Protein precipitation is more advisable and advantageous in the present work of FT and CDHP, because it could not only ensure a good cleanup of the plasma samples, adequate recoveries and high sensitivity, but also be performed simply. Moreover, an additional complicated derivatization pretreatment is unnecessary for the determination of CDHP by using the LC/MS/MS method instead of the GC/MS method.
Method validation
Selectivity and specificity. The selectivity of the method was assessed by comparing chromatograms of a standard solution, blank plasma and spiked plasma. The retention times were 1.5, 1.5 and 2.0 min for FT, CDHP and IS, respectively (Fig. 2) . As shown in the figure, there were no significant endogenous peaks that could interfere with the analytes and IS. The results indicate that the method exhibited both good specificity and selectivity. Matrix effect. The ion suppression/enhancement in the signal ranged from -8.9 to 5.3% and from -5.0 to 7.8% for FT and CDHP at the three QC levels, respectively, indicating that the matrix effect on the ionization of analytes is not obvious under these conditions. Linearity and lower limits of quantitation. The calibration curves ranged from 20 to 5000 ng/mL for FT, and ranged from 2 to 500 ng/mL for CDHP, respectively. The typical regression equations obtained by least-squares regression were y = 0.0011x + 0.0017 and y = 0.0053x + 0.0033 for FT and CDHP, respectively. Here, y is the peak-area ratios of analytes to IS, and x is the concentrations of the analytes. The correlation coefficient (r 2 ) was ≥0.9909 for all calibration curves, indicating a good linearity.
The LLOQ values of FT and CDHP were 20 and 2 ng/mL, respectively. At LLOQ, the accuracy was within ±4.7%, and the precision was less than 5.3% (n = 6) for all analytes, which was sufficient for pharmacokinetic studies of FT and CDHP in humans. Precision and accuracy. QC samples at three concentrations were analyzed in six replicates for determining the accuracy and precision of this method. As can be seen from Table 1 , the intra-and inter-assay precisions were less than 7.3 and 9.5% for FT and 8.6 and 8.3% for CDHP, respectively, and the accuracy was within ±4.4% for FT and ±7.5% for CDHP, respectively. All values were within the acceptable range, indicating that the present method has satisfactory accuracy, precision and reproducibility. Recovery. Under the given set of operating conditions, the recoveries of FT and CDHP from the human plasma at all concentration levels were 76.5 ± 5.2 and 78.3 ± 5.9%, respectively. The recovery was consistent over its calibration range, indicating that the extraction efficiency of the current method is independent of the concentrations in the ranges studied. The recovery of the IS was 89.9 ± 3.3%, and was steady throughout. Stability. The human plasma samples were stable after being placed at ambient temperature for 4 h, after being stored at -20 C for 30 days, or through three freeze-thaw cycles with the RSD being less than 11.5% and the RE within ±12.3% for all analytes. On the other hand, processed samples in the mobile phase were found to be stable in the auto-sampler at 4 C for a period of 12 h with the RSD being less than 6.7% and the RE within ±13.0% for all analytes, indicating that a large number of samples could be processed in each analytical run. Moreover, FT was not converted into 5-FU during all preparation steps or during the storage period.
Conclusions
In conclusion, a sensitive, specific, rapid and simple LC/MS/MS method was developed and validated for the simultaneous determination of FT and CDHP in human plasma. The plasma samples were prepared by protein precipitation, and followed by HPLC separation and MS/MS detection in a runtime of 3.5 min. Furthermore, the method required only 100 μL of plasma for the determination of all analytes, with the LLOQ of 20 and 2 ng/mL, respectively. The method can be applied to pharmacokinetic studies of S-1, FT or CDHP in humans.
On the other hand, because more than 52.8% of CDHP is excreted in urine, the renal function is critical for plasma CDHP clearance. 9 A lower CDHP clearance leads to prolonged high plasma concentrations of CDHP, which causes sustained high plasma concentrations of 5-FU by inhibiting the DPD activity. This may lead to severe adverse events. In clinical setting, patients with impaired renal functions are often encountered, for example elderly patients and patients with prior chemotherapy. 12 Thus, monitoring pharmacokinetics of CDHP, could prevent the occurrence of adverse events and optimize individual dose according to the patient's metabolic capacities. This would achieve an optimization of the treatment by increasing its efficacy and reducing the toxicity. Fig. 2 Typical SRM chromatograms of FT, CDHP and strychnine (IS): (A) blank human plasma with IS (100 ng/mL); (B) standard solution (FT, 400 ng/mL; CDHP, 40 ng/mL; IS, 80 ng/mL); (C) blank human plasma spiked with FT (500 ng/mL, 1.5 min), CDHP (50 ng/mL, 1.5 min) and IS (100 ng/mL, 2.0 min). 
